An artificial pancreas developed by researchers at the University of Cambridge has been granted approval by the USA’s Food and Drug Administration (FDA) for use by individuals with type 1 diabetes aged two and older, including during pregnancy.
The National Institute for Health and Care Excellence (NICE) has today (7 November 2023) recommended hybrid closed loop systems including the CamAPS FX app for use in managing type 1 diabetes, meaning that even more people living with the disease will be able to use this life-changing app.
An international trial to test whether an artificial pancreas can help young children manage their type 1 diabetes will begin next year, thanks to a major grant awarded by the European Commission.
Technology assisting people with type 1 diabetes edges closer to perfection.
The first natural birth to a mother with diabetes who has been fitted with an artificial pancreas took place this week. The device has been developed by researchers at the University of Cambridge.
Children with type 1 diabetes have been able to use pioneering artificial pancreas technology, developed at the University of Cambridge, for the first time overnight at home without the supervision of researchers.
Development of a sophisticated artificial pancreas holds potential to transform the lives of patients with Type 1 diabetes.
Cambridge research funded by the health charity Diabetes UK has for the first time successfully demonstrated the potential of an ‘artificial pancreas’ in preventing night-time hypoglycaemia in adults with Type 1 diabetes.
© 2024 University of Cambridge